Moderna (MRNA)
(Delayed Data from NSDQ)
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Zacks News
Pfizer COVID-19 Vaccine Data Raises Hopes for Industry, Economy
by Kinjel Shah
Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 90% effective in phase III.
2 Stocks to Watch on Pfizer's 90% Effective COVID-19 Vaccine
by Tirthankar Chakraborty
Pfizer's (PFE) shares hit an all-time high during yesterday's trading session on its milestone COVID-19 vaccine news, while Moderna's (MRNA) soared on optimism as it applies a similar technology.
Positive News on COVID-19 Vaccine
by Zacks Equity Research
Positive News on COVID-19 Vaccine
Pfizer's Covid Drug Proves 90%+ Effective; PFE, BNTX
by Mark Vickery
A Covid vaccine takes the lid off most everything market-related. That said, we're still looking at a period of months before it would be widely available.
Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances
by Zacks Equity Research
Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly. Shares up presumably on encouraging pipeline progress and rising cash resources.
Vertex (VRTX) Beats on Q3 Earnings & Sales, Ups Sales View
by Zacks Equity Research
Vertex (VRTX) beats estimates for both earnings and sales and raises revenue guidance for 2020.
Company News for Oct 30, 2020
by Zacks Equity Research
Companies in The News Are: NFLX, MRNA, IPHI, MRVL, RL.
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of -37.21% and 103.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Update on the COVID Vaccine Race
by John Blank
A 2021 Macro Recovery is About This, Alone.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.
The Zacks Analyst Blog Highlights: Netflix, Lockheed, Zoetis, ITUB and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Lockheed, Zoetis, ITUB and Moderna
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $70.53 in the latest trading session, marking a -0.44% move from the prior day.
Top Analyst Reports for Netflix, Lockheed Martin & Zoetis
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Netflix (NFLX), Lockheed Martin (LMT) and Zoetis (ZTS).
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon
by Zacks Equity Research
Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.
Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage
by Zacks Equity Research
Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $75.58, marking a -1.28% move from the previous day.
Moderna Gets Consent to File MAA for Coronavirus Vaccine in EU
by Zacks Equity Research
Moderna (MRNA) gets permission from the European Medicines Agency to submit a marketing authorization application for mRNA-1273, its vaccine candidate against COVID-19.
Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study
by Zacks Equity Research
Vaxart (VXRT) doses the first subject in an early-stage study of its oral coronavirus vaccine candidate VXA-CoV2-1. Stock rises.
J&J's Coronavirus Vaccine Studies Paused Post Adverse Event
by Zacks Equity Research
J&J's (JNJ) large phase III ENSEMBLE study on its coronavirus vaccine candidate, JNJ-78436735, is expected to enroll 60,000 adult participants and compares a single dose of the vaccine to placebo.
Zacks.com featured highlights include: NetEase, USA Truck, AXT and Moderna
by Zacks Equity Research
Zacks.com featured highlights include: NetEase, USA Truck, AXT and Moderna
Here's Why Small-Cap ETFs Are Hitting New Highs
by Sweta Killa
Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.
4 Stocks With Solid Earnings Acceleration to Watch
by Tirthankar Chakraborty
If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be called earnings acceleration.
Moderna (MRNA) Stock Moves -1.26%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $71.04, marking a -1.26% move from the previous day.